Zacks Investment Research downgraded shares of Orthopediatrics (NASDAQ:KIDS) from a hold rating to a strong sell rating in a research report sent to investors on Tuesday, Zacks.com reports.
According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “
Several other brokerages also recently issued reports on KIDS. BidaskClub upgraded shares of Orthopediatrics from a buy rating to a strong-buy rating in a research note on Wednesday, May 8th. BTIG Research reiterated a buy rating and issued a $44.00 target price on shares of Orthopediatrics in a research note on Friday, May 10th. Finally, JMP Securities initiated coverage on shares of Orthopediatrics in a research report on Wednesday, February 20th. They set an outperform rating and a $44.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the stock. Orthopediatrics presently has an average rating of Buy and an average price target of $41.00.
Shares of NASDAQ:KIDS opened at $41.02 on Tuesday. Orthopediatrics has a 52-week low of $18.77 and a 52-week high of $47.82. The stock has a market capitalization of $594.02 million, a P/E ratio of -42.73 and a beta of 0.04. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.54 and a quick ratio of 7.77.
Orthopediatrics (NASDAQ:KIDS) last issued its earnings results on Wednesday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04). Orthopediatrics had a negative net margin of 16.71% and a negative return on equity of 18.32%. The firm had revenue of $14.66 million during the quarter, compared to analyst estimates of $14.67 million. On average, sell-side analysts expect that Orthopediatrics will post -0.43 EPS for the current year.
A number of hedge funds have recently modified their holdings of the business. American International Group Inc. lifted its position in Orthopediatrics by 10.2% during the first quarter. American International Group Inc. now owns 5,025 shares of the company’s stock worth $222,000 after acquiring an additional 465 shares during the last quarter. Citigroup Inc. lifted its position in Orthopediatrics by 29.9% during the first quarter. Citigroup Inc. now owns 2,166 shares of the company’s stock worth $96,000 after acquiring an additional 499 shares during the last quarter. Blair William & Co. IL lifted its position in Orthopediatrics by 3.6% during the first quarter. Blair William & Co. IL now owns 14,490 shares of the company’s stock worth $641,000 after acquiring an additional 500 shares during the last quarter. Rhumbline Advisers lifted its position in Orthopediatrics by 6.6% during the first quarter. Rhumbline Advisers now owns 9,350 shares of the company’s stock worth $414,000 after acquiring an additional 580 shares during the last quarter. Finally, We Are One Seven LLC acquired a new stake in Orthopediatrics during the fourth quarter worth approximately $39,000. Hedge funds and other institutional investors own 45.03% of the company’s stock.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Read More: Retained Earnings
Get a free copy of the Zacks research report on Orthopediatrics (KIDS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.